Physician profile
Dino Ferrante
NPI 1104815471
$14,845.52
in general payments reported to CMS, 2019-2025
34 companies · $2,554 in 2025
The $2,554 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,723 · 2020: $661 · 2021: $2,380 · 2022: $2,577 · 2023: $2,460 · 2024: $2,491 · 2025: $2,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,360 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,360.19 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,034.23 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,051.22 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $2,677.64 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $831.79 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $474.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $444.91 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $346.40 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $320.09 | 2019-2024 | Linzess |
| Genzyme Corporation | $280.68 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $276.83 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $254.79 | 2019-2024 | Dificid |
| Gilead Sciences, INC. | $242.45 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $228.81 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $196.51 | 2019-2025 | Rebyota, Clenpiq |
| Allergan, INC. | $172.34 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $119.47 | 2021-2022 | |
| Intra-Sana Laboratories | $119.24 | 2022-2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Ardelyx, INC. | $119.11 | 2025 | Ibsrela |
| Boston Scientific Corporation | $117.88 | 2020-2025 | Resolution 360 Ultra Clip, General - Polypectomy |
| Phathom Pharmaceuticals, INC. | $93.28 | 2024-2025 | Voquezna |
| Ucb, INC. | $78.71 | 2019-2020 | |
| Pfizer INC. | $62.09 | 2019-2025 | |
| Lilly USA, LLC | $55.27 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $36.71 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $33.72 | 2022 | |
| Pentax of America, INC. | $32.43 | 2020 | |
| Braintree Laboratories, INC. | $24.60 | 2023 | Sutab |
| Biocompatibles, INC. | $22.83 | 2019 | |
| Novo Nordisk INC | $18.87 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $17.17 | 2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $17.04 | 2022 | |
| Aimmune Therapeutics, INC. | $16.59 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $16.06 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dino Ferrante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.